Large 22q13.3 deletions perturb peripheral transcriptomic and metabolomic profiles in Phelan-McDermid syndrome

• Published in: HGG advances Vol. 4; no. 1; p. 100145
• Main Authors: Breen, Michael S., Fan, Xuanjia, Levy, Tess, Pollak, Rebecca M., Collins, Brett, Osman, Aya, Tocheva, Anna S., Sahin, Mustafa, Berry-Kravis, Elizabeth, Soorya, Latha, Thurm, Audrey, Powell, Craig M., Bernstein, Jonathan A., Kolevzon, Alexander, Buxbaum, Joseph D., Warfield, Simon K., Scherrer, Benoit, Filip-Dhima, Rajna, Dies, Kira, Siper, Paige, Hanson, Ellen, Phillips, Jennifer M.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 12.01.2023; Elsevier
• Subjects: autism spectrum disorder; immunogenetics; immunophenotyping; Metabolomics; multi-omics; Nerve Tissue Proteins - genetics; rare disorders; SHANK3; Sphingolipids; Transcriptome - genetics; multi-omics; immunogenetics; autism spectrum disorder; immunophenotyping; rare disorders; SHANK3
• ISSN: 2666-2477; 2666-2477
• DOI: 10.1016/j.xhgg.2022.100145

Phelan-McDermid syndrome (PMS) is a rare neurodevelopmental disorder caused at least in part by haploinsufficiency of the SHANK3 gene, due to sequence variants in SHANK3 or subtelomeric 22q13.3 deletions. Phenotypic differences have been reported between PMS participants carrying small “class I” mutations and large “class II” mutations; however, the molecular perturbations underlying these divergent phenotypes remain obscure. Using peripheral blood transcriptome and serum metabolome profiling, we examined the molecular perturbations in the peripheral circulation associated with a full spectrum of PMS genotypes spanning class I (n = 37) and class II mutations (n = 39). Transcriptomic data revealed 52 genes with blood expression profiles that tightly scale with 22q.13.3 deletion size. Furthermore, we uncover 208 underexpressed genes in PMS participants with class II mutations, which were unchanged in class I mutations. These genes were not linked to 22q13.3 and were strongly enriched for glycosphingolipid metabolism, NCAM1 interactions, and cytotoxic natural killer (NK) immune cell signatures. In silico predictions estimated a reduction in CD56+ CD16– NK cell proportions in class II mutations, which was validated by mass cytometry time of flight. Global metabolomics profiling identified 24 metabolites that were significantly altered in PMS participants with class II mutations and confirmed a general reduction in sphingolipid metabolism. Collectively, these results provide new evidence linking PMS participants carrying class II mutations with decreased expression of cytotoxic cell signatures, reduced relative proportions of NK cells, and lower sphingolipid metabolism. These findings highlight alternative avenues for therapeutic development and offer new mechanistic insights supporting genotype-to-phenotype associations in PMS. Breen et al. apply a multi-omic approach to dissect the immunogenetics of Phelan-McDermid syndrome (PMS), revealing alterations in the peripheral transcriptome, metabolome, and among innate immune cell proportions in PMS participants harboring large 22q13.3 deletions. These findings highlight PMS immunopathology and new biomarkers for diagnostics and treatment response studies.